Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 >= 1% status confers therapeutic sensitivity to Cisplatin, Nivolumab, Pemetrexed in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer at high risk of recurrence whose tumors have PD-L1 expression >= 1%. The treatment regimen contians five treatment schedules: (1) nivolumab 360 mg, CARBOplatin (AUC6), and PAClitaxel (200 mg/m^2); (2) nivolumab 360mg, gemcitabine (1000 mg/m^2), and CARBOplatin (AUC5); (3) nivolumab 360 mg, gemcitabine 1250 mg/m^2, and CISplatin 75 mg/m^2; (4) nivolumab 360 mg, PEMEtrexed, and CARBOplatin with folic acid or multivtamin containig 350-1000 micrograms of folic acid; and (5) nivolumab 360 mg, PEMEtrexed, and CISplatin along with folic acid or multivitamin containig 350-1000 mg of folic acid.
This statement is based on a regulatory approval from the Health Service Executive:
Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.